KALA Nilai Total Aset Perusahaan Kala Pharmaceuticals

KALA (kalarx.com) - tandha merek perusahaan

KALA BIO, Inc. (KALA) possesses exceptional influence within its segment due to inelastic demand for unique MSC-exosomes for corneal regeneration. The stock's price history reflects the dynamics of total assets, which amount to 23.32, highlighting the expansion of the stem cell secretome platform. Business development relies on strategic partnerships with specialized clinics to create cutting-edge therapeutic solutions.

KALA (KALA BIO) riwayat Total Aset Perusahaan saka 04.07.2022 nganti 31.10.2026

Rincian analitis lan laporan data perusahaan kalarx.com (KALA)

- nilai pasar lan prakiraan target analis:
Rega saham KALA BIO|KALA - Bagan rega target
- data kapitalisasi pasar:
Biji pasar KALA BIO, Inc.|KALA - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi Saham KALA BIO|KALA - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku kalarx.com|KALA - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi KALA BIO, Inc.|KALA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas KALA BIO|KALA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku KALA BIO, Inc.|KALA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan KALA BIO|Likuiditas darurat kalarx.com
- indikator pendapatan resik lan kelipatan nilai:
KALA - Penghasilan resik
Pambiji fundamental:KALA BIO, Inc.
Produk sing diprodhuksi KALA BIO Inc.

For a biotech company with unique MSC-exosome technology and pricing power in ophthalmology, the volume of resources determines the scaling potential of the therapy. This metric is calculated inversely via return on assets (ROA), combining equity and liabilities. By analyzing the total assets chart, an investor can differentiate balance sheet degradation from a temporary discount. The dynamics of this metric objectify the fundamental business value of KALA BIO, Inc. (KALA).

Pesaing wigati

alcon.com (ALC) - Total Aset Perusahaan|Aset Agregat Perusahaan Bausch + Lomb|Glaukos Corp - Nilai Total Aset Perusahaan|Total Aset Perusahaan APLS|BLTE (Belite Bio Inc) - Nilai Agregat Aset|Total Aset Perusahaan OCUL (Ocular Therapeutix)|Total Aset Perusahaan harrowinc.com HROW|VRDN - Aset Agregat Perusahaan|Nilai Agregat Aset LENZ (LENZ Therapeutics Inc)|Oculis (OCS) - Aset Agregat Perusahaan|Gunggung Aset Perusahaan EyePoint Corp|KOD (Kodiak Sciences Inc.) - Total Aset Perusahaan|Total Aset Perusahaan Aldeyra|Gunggung Aset Perusahaan IRD (Opus Genetics Inc)|OKYO (okyopharma.com) - Nilai Agregat Aset|Total Aset Perusahaan ADVM (Adverum Biotechnologies, Inc.)|Outlook Therapeutics Corp (OTLK) - Aset Perusahaan|CLSD: Gunggung Aset Perusahaan|Aset Perusahaan NovaBay Pharmaceuticals|KPRX: Total Aset Perusahaan|Aset Perusahaan Alimera Sciences, Inc. (ALIM)|Aset Agregat Perusahaan Eyenovia Inc.|Guardion Health (GHSI) - Gunggung Aset Perusahaan|Aset Agregat Perusahaan Ocuphire Pharma, Inc. (OCUP)|Total Aset Perusahaan opthea.com (OPT)